FDA approval of Orca Bio’s Tregzi makes it the first cell therapy based on regulatory T cells, or Tregs. Clinical trial results showed reduced risk of graft-versus-host disease, a common complication of the allogeneic stem cell transplants that are a standard treatment for certain blood cancers.
The post Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine appeared first on MedCity News.
